ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of EUR 42.93 million. The enterprise value is 40.80 million.

Market Cap	42.93M
Enterprise Value	40.80M

Important Dates

The next estimated earnings date is Wednesday, March 12, 2025.

Earnings Date	Mar 12, 2025
Ex-Dividend Date	n/a

Share Statistics

ABIONYX Pharma has 34.68 million shares outstanding. The number of shares has increased by 11.19% in one year.

Current Share Class	n/a
Shares Outstanding	34.68M
Shares Change (YoY)	+11.19%
Shares Change (QoQ)	+7.17%
Owned by Insiders (%)	31.53%
Owned by Institutions (%)	0.03%
Float	18.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.00
PB Ratio	4.25
P/TBV Ratio	10.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.15
EV / Sales	8.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.19

Financial Position

The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.34.

Current Ratio	2.28
Quick Ratio	2.17
Debt / Equity	0.34
Debt / EBITDA	n/a
Debt / FCF	-1.03
Interest Coverage	-122.52

Financial Efficiency

Return on equity (ROE) is -47.16% and return on invested capital (ROIC) is -19.04%.

Return on Equity (ROE)	-47.16%
Return on Assets (ROA)	-14.12%
Return on Capital (ROIC)	-19.04%
Revenue Per Employee	79,607
Profits Per Employee	-55,049
Employee Count	61
Asset Turnover	0.33
Inventory Turnover	21.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.07% in the last 52 weeks. The beta is -0.03, so ABIONYX Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.03
52-Week Price Change	-7.07%
50-Day Moving Average	1.28
200-Day Moving Average	1.21
Relative Strength Index (RSI)	45.75
Average Volume (20 Days)	39,519

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of EUR 4.86 million and -3.36 million in losses. Loss per share was -0.11.

Revenue	4.86M
Gross Profit	932,000
Operating Income	-3.31M
Pretax Income	-3.36M
Net Income	-3.36M
EBITDA	-3.19M
EBIT	-3.31M
Loss Per Share	-0.11

Full Income Statement

Balance Sheet

The company has 5.30 million in cash and 3.17 million in debt, giving a net cash position of 2.13 million or 0.06 per share.

Cash & Cash Equivalents	5.30M
Total Debt	3.17M
Net Cash	2.13M
Net Cash Per Share	0.06
Equity (Book Value)	9.45M
Book Value Per Share	0.29
Working Capital	4.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.03 million and capital expenditures -59,000, giving a free cash flow of -3.09 million.

Operating Cash Flow	-3.03M
Capital Expenditures	-59,000
Free Cash Flow	-3.09M
FCF Per Share	-0.09

Full Cash Flow Statement

Margins

Gross margin is 19.19%, with operating and profit margins of -68.12% and -69.15%.

Gross Margin	19.19%
Operating Margin	-68.12%
Pretax Margin	-69.15%
Profit Margin	-69.15%
EBITDA Margin	-65.65%
EBIT Margin	-68.12%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.19%
Shareholder Yield	-11.19%
Earnings Yield	-8.65%
FCF Yield	-7.20%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABIONYX Pharma has an Altman Z-Score of 3.42.

Altman Z-Score	3.42
Piotroski F-Score	n/a